- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00443508
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion
Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study
This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.
The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.
The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.
The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.
The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.
Patients will undergo the following baseline studies:
- Doppler ultrasound to exclude any mechanical or a vascular problem.
- A kidney biopsy to define the histological changes (degree of interstitial fibrosis, tubular and glomerular changes). The biopsies will be stained also for C4D and for fibrinogenic markers (TGF-beta, and collagen).
- A 24-hour urine protein excretion and creatinine clearance
- Echocardiography study
- Carotid Ultrasound
The following parameters will be monitored every clinic visit throughout the study period:
- SMA-12 including creatinine levels.
- A complete blood count.
- Cholesterol, HDL-cholesterol and triglyceride levels.
- Blood pressure measurements (X2)
- The number of blood pressure medications.
- Cholesterol lowering medication requirement
- Urine protein excretion (quantitative spot-test )
- Protein amount in the urine
Study end points:
The data will be evaluated based on an intention to treat analysis and the following parameters will be compared between the two groups:
- Creatinine levels and calculated creatinine clearance
- Spot urine for Cr./protein ratio
- 24-hr. protein excretion
- Change in peak diastolic and mean arterial blood pressure
- The number and dosage of blood pressure medications
- Cholesterol, HDL and triglyceride levels
- Proportion of patients on cholesterol lowering agents
- Number and severity of biopsy proven acute rejection episodes
- Incidence of biopsy proven chronic rejection. (depends on per protocol biopsy at end of study)
- Patient and graft survival
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Petach Tikva, Israel, 49202
- Recruiting
- Transplantation department, rabin Medical Center
-
Contact:
- Eytan Mor, Prof
- Phone Number: 00937 3 9376528
- Email: tikim@clalit.org.il
-
Principal Investigator:
- Eytan Mor, Prof
-
Sub-Investigator:
- Ruti Rahamimov, Dr
-
Sub-Investigator:
- Alex Yusim, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients on CNI FK < 5 ng/m"l with MPA / Imuran with or without steroids
- Renal impairment GFR between 30 - 70 m"l/minute/
- Patient who signed Informed consent
- Patient with no contraindication to renal biopsy
- Women who are not pregnant and will use contraception
Exclusion Criteria:
- Proteinuria > 100 m"g/mmol Creatinine
- Acute rejection during 3 months before screening
- WBC < 2500, plt < 50,000,
- Nephropathy due to polyoma virus
- Patients on other investigational drugs
- Patients on rapamycin
- Patients with HIV or other systemic infection
- Inability to comply with protocol requirements
- Active or history of malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
The primary goal is to assess the change in renal function
|
|
at 6 and 12 months after conversion using creatinine levels
|
|
and calculated creatinine clearance.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
The secondary aim is to assess changes in cardiovascular risks at
|
|
12 months after conversion (glucose control., cholesterol and
|
|
triglyceride levels and hypertension control), incidence of
|
|
acute and chronic rejection and graft and patient survival rates.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Eytan Mor, Prof, Rabin Medical Center, head of Transplantation department
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRAD001AIL01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.